), we demonstrated that tumor necrosis factor (TNF)-␣ inhibited the activity of CTP:phosphocholine cytidylyltransferase (CT), the rate-limiting enzyme in the de novo synthesis of phosphatidylcholine (PC), and that its actions were likely exerted through a metabolite of sphingomyelin. In this paper, we explore the signaling pathway employed by TNF-␣ using C2 ceramide as a cell-penetrating sphingolipid representative of the metabolites induced by TNF-␣. We found that in H441 cells, as reported in other cell types, cytosolic phospholipase A2 (cPLA2) is activated by TNF-␣. We also observed that the inhibiting action of C2 ceramide on CT requires protein kinase C-␣, p38 mitogenactivated protein kinase, and cPLA2. The actions of C2 ceramide on CT activity can be duplicated by adding 2 M lysoPC to these cells. Furthermore, we found that the effects of C2 ceramide are dependent on 5-lipoxygenase but that cyclooxygenase II is unimportant. We hypothesize that CT activity is inhibited by the lysoPC generated as a consequence of the activation of cPLA2 by protein kinase C-␣ and p38 mitogen-activated protein kinase. The other product of the activation of cPLA2, arachidonic acid, is a substrate for the synthesis of leukotrienes, which raise intracellular Ca 2ϩ levels and complete the activation of cPLA2. lung injury; pulmonary surfactant; phosphatidylcholine synthesis; leukotrienes; cytidine 5Ј-triphosphate; protein kinase C; mitogen-activated protein kinase; cytosolic phospholipase A2
lung injury; pulmonary surfactant; phosphatidylcholine synthesis; leukotrienes; cytidine 5Ј-triphosphate; protein kinase C; mitogen-activated protein kinase; cytosolic phospholipase A2 THE METABOLISM OF PULMONARY SURFACTANT is impaired during the development of chronic lung diseases of the newborn (28) and adult (37) , presumably in response to unidentified materials generated during the course of these injuries. Among the several growth factors and cytokines that are released is tumor necrosis factor (TNF)-␣, an important cytokine that mediates a variety of cellular functions in the inflammatory response (for example, see Refs. 30, 34) . TNF-␣ has also been shown to inhibit the synthesis of surfactant in pulmonary epithelial cells (21, 36, 45, 55) , and in the preceding companion paper (53) , our laboratory demonstrated that its effects on phosphatidylcholine (PC) synthesis may be through the actions of metabolic products of sphingomyelin hydrolysis acting on CTP: phosphocholine cytidylyltransferase (CT; EC 2.7.7.15). In this paper, we studied the signaling pathway(s) initiated by sphingomyelin metabolites to effect this inhibition of CT. Using plasmid vector constructs of dominant negative protein kinase C (PKC)-␣, hypothesized to be involved in the signaling pathway together with relatively specific inhibitors of other purported intermediates, we found that PKC-␣, p38 mitogenactivated protein kinase (MAPK), and cytosolic phospholipase A 2 (cPLA 2 ; type IV) are all required for the ceramide-induced inhibition of CT activity. Furthermore, we determined that an inhibitor of 5-lipoxygenase was also able to nullify the actions of ceramide, whereas an inhibitor of cyclooxygenase-2 (COX-2) had no effect. A hypothesis is presented, based on these data as well as findings in the literature (11) , which suggests that the inhibition of CT is from the generation of lysoPC through the action of activated cPLA 2 . Arachidonic acid, the other product of the hydrolysis of sn-2-arachidonoyl PC, is a substrate for the synthesis of leukotrienes, which may stimulate Ca 2ϩ influx (23, 46) and thereby further activate cPLA 2 (33) or may directly stimulate the transcription of TNF-␣ (48) .
were from Calbiochem (La Jolla, CA). [␥- 32 P]ATP, [ 32 P]orthophosphoric acid, L-␣-1-palmitoyl-2-arachidonyl-[arachidonyl- 1- 14 C]PC, and [methyl- 14 C]phosphorylcholine were obtained from NEN (Boston, MA). NS-398 and nordihydroguaiaretic acid (NDGA) were from BIOMOL (Plymouth Meeting, PA).
Plasmid constructs. Kinase-inactive PKC-␣ (lysine in ATP-binding site mutated to methionine) (7) cloned into pTB701/HA was obtained from Dr. Robert V. Farese (University of South Florida College of Medicine, Tampa, FL). Antisense (dominant negative) and wild-type PKC-␣ cloned into pRSV (43) were obtained from Dr. Robert I. Glazer (Georgetown University Medical Center, Washington, DC) (2) .
Cell culture. H441 cells (human lung adenocarcinoma cells) were obtained at the 50th passage from the ATCC. The cells were maintained in McCoy's 5A medium containing 5% fetal bovine serum (FBS) and 50 g/ml of gentamicin sulfate at 37°C in a 5% CO 2-95% air humidified atmosphere. Before all experiments, the medium was changed to McCoy's 5A medium without FBS and the cells were conditioned overnight. All experiments were conducted in medium without FBS.
Stable transfection with constructs of PKC-␣. We used TransIT-LT1 transfection reagent (PanVera) following the manufacturer's instructions. Briefly, H441 cells at 30-40% confluence were incubated with a complex of plasmid DNA and the LT1 transfection reagent (1 g to 4 l) and were cotransfected with pCEV or pCDNA (neo r ) plasmids to allow selection with Geneticin (G418, Life Technologies, Gaithersburg, MD). The cells were washed twice with serum-and gentamicin-free McCoy's 5A medium, and the transfection mix of DNA and transfection reagent prepared in the same medium was overlaid on the cells. After 48 h of incubation, the transfected cells were trypsinized and selected with 500 g/ml of Geneticin for a period of 3-4 wk. Heterogeneous populations of transfected cells were then trypsinized and maintained in medium containing G418 for Ͼ4 passages.
PKC activity. PKC activity in the cytosolic and membrane fractions was measured by the method of Chakravarthy et al. (13) . Briefly, cells were grown to 60-70% confluence and then deprived of serum for 24 h. After treatment, the cells were washed twice with Ca 2ϩ -and Mg 2ϩ -free PBS and scraped into ice-cold lysis buffer containing 1 mM NaHCO 3, pH 7.5, 5 mM MgCl 2, 100 M phenylmethylsulfonyl fluoride (PMSF), 10 g/ml of leupeptin, 10 g/ml of pepstatin, and 100 M sodium orthovanadate. Cells were homogenized and vortexed for 1 min, and the homogenates were centrifuged at 45,000 rpm (TLA 45 rotor, Beckman TLX centrifuge) for 15 min at 4°C. Supernatant (cytosolic fraction) was collected, and the pellet (membrane fraction) was homogenized in 2ϫ assay buffer (50 mM Tris ⅐ HCl, pH 7.5, 10 mM CaCl2, 200 M sodium pyrophosphate, 2 mM sodium fluoride, and 200 M PMSF). The activity assay was carried out on the same day.
The assay was standardized for all the fractions (cell lysate, cytosol, and membrane) with different amounts of protein and time and temperature of the incubation. PKC activity [counts per minute (cpm) per microgram of total protein] was linear for 2-30 g of protein and the 10-to 30-min incubation period. The correlation coefficient was 0.97-0.99. The assay was carried out with 5-20 g of protein in buffer containing 25 mM Tris ⅐ HCl, pH 7.5, 2.5 mM MgCl2, 0.5 M CaCl2, 50 M sodium pyrophosphate, 0.5 mM sodium fluoride, 50 M PMSF, 20 M ATP, 3 g of the MBP [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] peptide fragment substrate, 1 Ci of [ 32 P]ATP, 0.015 g of diolein, and 0.1 g of phosphatidylserine. After 15 min of reaction at room temperature, 20 l of the reaction mixture were spotted on phosphocellulose paper disks (Life Technologies). The disks were washed three times with 0.1% acetic acid and twice with deionized water and counted in 5 ml of scintillation fluid. Counts per minute were normalized with total protein in each fraction.
PKC isoform-specific kinase activity. Isoform-specific activity was determined by slight modifications of the methods described by Denning et al. (17) and Bandyopadhyay et al. (8) . The assay was standardized with different amounts of protein from different cellular fractions, with different amounts of antibody, and by varying the incubation time for immunoprecipitation (4 and 16 h). The standard curves for PKC-␣ and PKC-␤II activities were linear up to 500 g of protein for all the cellular fractions. Correlation coefficients for standard curves for PKC activity (cpm/g protein) varied from 0.89 to 0.995.
Briefly, ϳ200 g of protein from whole cell lysates, the cytosolic fraction, or membrane fractions were suspended in buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM sodium orthovanadate, 1.5 mM EGTA or CaCl 2, 10 M sodium fluoride, 1 mM PMSF, 10 g/ml of leupeptin, and 10 g/ml of pepstatin. Immunoprecipitation was performed for 16 h with 0.6 g of polyclonal antibodies against PKC-␣ and PKC-␤II and 20 l of protein A agarose at 0-4°C. The immunoprecipitates were washed and resuspended in 25 l of 50 mM Tris ⅐ HCl, pH 7.5, and 5 mM 2-mercaptoethanol. To start the reaction, kinase assay buffer (see above) was added to the immunoprecipitated PKC, and the method thereafter was essentially identical to the one described above. The MBP 4-14 peptide was used for measuring activity.
MAPK phosphorylation (activation). Cells seeded in 60-mm tissue culture dishes were treated with TNF-␣ (10 ng/ml) for various time periods. The cells were washed twice with PBS and lysed in 200 l of Tris ⅐ HCl buffer (pH 7.4) containing 25 mM Tris, 1% Igepal, 150 mM NaCl, 50 mM NaF, 200 M sodium orthovanadate, and 1 mM PMSF. The lysates were probe-sonicated for 5 s and centrifuged at 14,000 rpm for 10 min to remove the cell debris. Lysate protein was separated on 10% SDS-polyacrylamide, and the gels were blotted with anti-phospho-specific p38 MAPK. Blotting the membranes with anti-p38 MAPK antibodies confirmed equal protein loading in the gels. The proteins of interest were detected with an enhanced chemiluminescence kit. The MAPK antibodies were obtained from New England BioLabs (Beverly, MA) and were used at 1:1,000 dilution in Trisbuffered saline containing 5% BSA and 0.2% Tween 20. The anti-rabbit IgG-horseradish peroxidase secondary antibody was from Santa Cruz Biotechnology and was used at 1:5,000 dilution with blocking buffer (10% milk in Tris-buffered saline-2% Tween 20).
CT activity. We used the method of Ansel and Chojnacki (22) . Cells were washed twice with normal saline, harvested, and homogenized in 200 l of homogenization buffer (50 mM Tris ⅐ HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 2 mM dithiothreitol, 175 g/ml of PMSF, 5 mM sodium fluoride, and 0.1 mM sodium orthovanadate). Homogenates were sonicated in a water bath sonicator for 20 min and centrifuged (14,000 rpm) for 5 min to isolate the membrane fraction. Membrane pellets were then homogenized in 200 l of the homogenization buffer.
For the activity assay, 20 g of membrane protein were mixed with assay buffer (400 mM Tris ⅐ HCl, pH 7.5, 30 mM magnesium acetate, 10 mM CTP, and 50,000 cpm of [ 14 C]phosphorylcholine) and incubated at 37°C for 1 h. To stop the reaction, the tubes were immersed in a boiling water bath for 2 min. Radioactive CDPcholine was extracted on acid-washed charcoal, and the charcoal was washed three times with water before extraction with formic acid for scintillation counting.
CT phosphorylation. Cells were labeled with [ 32 P]orthophosphate (100 Ci/60-mm dish) for 18 h in phosphate-free DMEM. The labeled cells were stimulated with TNF-␣ (100 ng/ml) or ceramide (10 g/ml). After specified times (0, 1, 3, and 5 h), the cells were washed with ice-cold PBS and lysed in Tris⅐HCl buffer (pH 7.4) containing 25 mM Tris, 1% Igepal, 150 mM NaCl, 50 mM NaF, 200 M sodium orthovanadate, and 1 mM PMSF. One hundred micrograms of lysate protein were mixed with 10 l of a polyclonal antiserum against human CT and incubated overnight at 5°C. The antiserum was a mixture of antibodies developed to the peptide sequences acetyl-AKVNARKRRKEAPGC-amide and acetyl-NEKKYHLQERVD-KVC-amide (QCB, Hopkinton, MA). The immune complex was captured on protein A agarose beads, and the bound radioactivity was eluted in SDS-PAGE loading buffer (75 l). A portion of the elute was directly counted by scintillation counting, and the rest was loaded on a 10% polyacrylamide gel for further separation and autoradiography.
In some experiments, we measured the incorporation of [ 32 P]orthophosphate into serine, threonine, and tyrosine after hydrolysis of the CT protein and the separation of amino acids by HPLC. Cells were labeled overnight with [ 32 P]orthophosphate. The next morning, the medium was removed and the cells were given TNF-␣ or the control vehicle. At varying times, the cells were washed, harvested, and homogenized. The lysate was immunoprecipitated with the antibody to CT, and the immunoprecipitate was hydrolyzed in a sealed, evacuated tube with 6 N HCl for 3 h. The samples were then lyophilized, mixed with carrier phosphotyrosine, phosphoserine, and phosphothreonine, and derivatized with 9-fluorenylmethoxycarbonyl (FMOC). Excess FMOC was removed by solvent partition with pentane, the sample was filtered, and the mixture was eluted on a column of Partisil 10 SAX (Phenomenex, Torrance, CA) with an isocratic solution of 55% methanol, 1% tetrahydrofuran, and 10 mM potassium phosphate, pH 3.9. The column was monitored by on-line fluorescence, and the peaks corresponding to phosphotyrosine, phosphoserine, and phosphothreonine were eluted, dried, and counted.
PLA 2 activity. We measured PLA2 activity in the cytosol of the cells by the hydrolysis of a substrate of radioactive sn-2-arachidonoyl PC. Cells were seeded in 60-mm plates and allowed to attach for 4-6 h in 1.5 ml of 10% FBS-McCoy's 5A medium. The cells were then washed twice with serum-free McCoy's medium and equilibrated overnight (17-18 h) in 1.5 ml of serum-free McCoy's medium. After treatment with 10 M C 2 ceramide, the cells were washed twice with ice-cold PBS and harvested in 100 l of a buffer containing 250 mM sucrose, 2 mM EDTA, 50 mM HEPES, pH 7.5, 20 g/ml of leupeptin, and 1 mg/ml of PMSF. The cells were sonicated and centrifuged at 45,000 rpm for 30 min. The cytosolic fraction was used for the assay of cPLA 2. The substrate,
was suspended in DMSO with vigorous vortexing. Five microliters of the substrate were mixed with 10 l of CaCl2 solution and 10 l of BSA solution in a glass tube (final assay concentration of the substrate was 6 M). The assay was initiated by adding 30-40 g of the protein and incubating for 30-60 min at 37°C. The products of the reaction were separated by silicic acid TLC, and the radioactive fatty acid was spot-scraped and counted. . A: cells were handled as described in Fig. 1 and were given the cytokines in serum-free medium for indicated times. Cell lysates given TNF-␣ were processed for Western blots with 25 g of lysate protein loaded in each lane and were blotted with either antisera specific for phosphorylated (phospho; ϩPhos) p38 MAPK (activated) or nonphosphorylated (ϪPhos) p38 MAPK (total). B: experiments with C2 ceramide were processed similarly but were blotted only with anti-phosphorylated MAPK, with controls at each time point. In separate experiments, we found that the phosphorylation of p38 MAPK in control cells did not change within the first 5 min (data not shown). Values are means Ϯ SE from 3 experiments.
Incorporation of [
32 P]orthophosphoric acid into PC. Cells (0.2-0.3 X 10 6 /well), either normal H441 or cells transfected with PKC-␣ constructs, were seeded on six-well tissue culture plates (Corning, New York, NY). After overnight growth, the cells were starved for 18-24 h in phosphate-free DMEM without serum. The cells were then treated with 10 M C 2 ceramide or DMSO (vehicle control) for varying times. At the end of the treatments, the cells were further incubated for 5 h with 10 Ci of [ 32 P]orthophosphoric acid without removing the C2 ceramide (a total of 6 h of ceramide exposure). Cells were washed twice with PBS, harvested in 400 l of deionized water, and homogenized.
Total lipids from cell homogenates were extracted by the method described by Bligh and Dyer (10) . The lipids were separated on silica gel TLC plates with chloroform-methanol-28% ammonia (65:25:5 vol/vol). Phospholipids were visualized under ultraviolet light after being sprayed with 2-( ptoluidino)naphthalene-6-sulfonic acid (0.36% wt /vol). The PC band was scraped for counting, and the counts were normalized to total cellular protein.
Statistical analyses. We used one-way ANOVA or t-test to test for significance. Significance was assumed for P Ͻ 0.05, with P Ͻ 0.1 noted.
RESULTS

TNF-␣ and C 2 ceramide increase PKC-␣ activity in H441 cells. TNF-␣ (38, 44
) and ceramide (24, 40) have been shown to both activate and inhibit PKC depending on cell type and PKC isoform. In bronchial epithelial cells (56) , TNF-␣ is an activator. We tested whether this TNF-␣-induced stimulation holds in H441 cells when focusing on PKC-␣. The results are shown in Fig.  1 . Cells treated with 10 ng/ml of TNF-␣ showed PKC-␣ activity that was elevated threefold. Peak activity occurred within 30 min, the earliest time interval analyzed. There was no change in the activity of PKC-␤II (data not shown). In one experiment, we also found that 10 M C 2 ceramide increased PKC-␣ activity by ϳ50% within 1 min, and this remained elevated through 3 h.
TNF-␣ increases MAPK activity in H441 cells. TNF-␣ and ceramide have been widely reported to activate MAPKs (see, for example, Ref. 47) , and this was reproduced in H441 cells as shown in Fig. 2 . TNF-␣ activates (phosphorylates) p38 MAPK maximally within 15 min, consistent with a report in other cell types (39) . Similar results were found in separate experiments with 10 M C 2 ceramide (Fig. 2) , with peak activation occurring after 5 min.
C 2 ceramide inhibits CT activity; the effect is abolished in cells transfected with dominant negative clones of PKC-␣. We first established that PKC-␣ activity was altered in the cells that we transfected with PKC-␣ constructs. The results are shown in Fig. 3 . Activity of PKC-␣ in the two dominant negative transfected clones was reduced to ϳ60% of that in nontransfected control cells but was unchanged in the wild-type PKC-␣ transfectants.
We next measured CT activity in these transfected cells to determine if changing PKC-␣ activity affected the basal level of CT activity or the ability of ceramide to inhibit CT. Basal CT activity (activity in the absence of ceramide treatment) was not changed in any of the transfected cells. As expected [see companion paper (53)], 10 M C 2 ceramide reduced CT activity by 50-70% in nontransfected cells. However, the inhibition of CT activity by 10 M C 2 ceramide was abolished in cells transfected with two dominant negative constructs of PKC-␣ but not in cells transfected with wild-type PKC-␣ or the cloning vector (Fig. 4) . These data suggest that PKC-␣ is a critical part of the sig- Ceramide-induced inhibition of CT activity requires a functional cPLA 2 but not iPLA 2 . cPLA 2 has been reported to be activated in a number of cell types in response to TNF-␣ (19, 33, 41) . We confirmed this activity in H441 cells with C 2 ceramide. cPLA 2 was rapidly activated, and activity remained elevated at ϳ150% of control value for at least 60 min (Fig. 5) . Consistent with this response, we also found in one experiment that the phosphorylation of immunoprecipitated cPLA 2 was increased by 58% after cells were exposed to 10 M C 2 ceramide for 15 min. This increase in phosphorylation was maintained through 30 min but reversed by 1 h. The results indicate that C 2 ceramide exerts an activation of cPLA 2 similar to that reported for TNF-␣.
We used two inhibitors of PLA 2 : BEL, a relatively specific inhibitor of iPLA 2 (6), and AACOCF 3 , a compound that inhibits cPLA 2 (1). Both compounds were administered to H441 cells at three concentrations, either with or separately from 10 M C 2 ceramide. The results are shown in Fig. 6 . AACOCF 3 at all concentrations effectively blocked the ceramide-induced inhibition of CT activity; BEL had no effect. Neither compound affected basal CT activity. The results indicate that a functioning cPLA 2 is required for the ceramide- Membrane protein (20 g) was mixed with assay buffer (400 mM Tris ⅐ HCl, pH 7.5, 30 mM magnesium acetate, 10 mM CTP, and 50,000 cpm of [ 14 C]phosphorylcholine) and incubated at 37°C for 1 h. To stop the reaction, tubes were immersed in a boiling water bath for 2 min. Radioactive CDPcholine was extracted on acid-washed charcoal, and the charcoal was washed 3 times with water before extraction with formic acid for scintillation counting. Values are means Ϯ SE from 3 independent experiments. *P Ͻ 0.05 compared with cells undergoing the same transfection protocol but not receiving C2 ceramide. induced inhibition, whereas iPLA 2 does not appear to be involved.
SB-203580, a relatively specific inhibitor of p38 MAPK, abolished the ceramide inhibition of CT; it had no effect on basal CT activity.
We pretreated cells with 2 M SB-203580 for 1 h and then added 10 M C 2 ceramide (SB-203580 remained in the medium). We harvested cells after 1 and 3 h of ceramide and measured CT activity in the membrane fraction of the cell lysates. The results are shown in Fig. 7 . As expected, ceramide reduced CT activity to ϳ60% of control values (P Ͻ 0.05). SB-203580 (2 M) had no effect on basal CT activity (control vs. 2 M SB-203580) but significantly reduced the ability of C 2 ceramide to inhibit CT activity (2 M SB-203580 plus ceramide vs. control, not significant, P Ͼ 0.05). We also found in one experiment that the increase in phosphorylation of cPLA 2 induced by 10 M C 2 ceramide was inhibited by SB-203580. This suggests that the ceramide signaling to CT involves both cPLA 2 and p38 MAPK, the latter possibly serving to activate cPLA 2 by phosphorylation.
The signaling pathway for ceramide-induced inhibition of CT involves a leukotriene generated through 5-lipoxygenase. We used NDGA (22) , a compound that inhibits the lipoxygenases, principally, 5-lipoxygenase. We used two concentrations of NDGA, 1 and 5 M, which we gave to the cells together with 10 M C 2 ceramide. The results obtained with both concentrations were indistinguishable, and the data from the use of 1 M NDGA are shown in Fig. 8 . NDGA completely prevented the C 2 ceramide inhibition of CT.
Inhibition of CT does not involve an eicosanoid generated through COX-2. Two COXs have been described in the literature: a constitutively expressed enzyme, COX-1, and an induced enzyme, COX-2 (50). Most cytokine-induced actions involving COXs are through COX-2 (50). We used a relatively specific inhibitor for COX-2, NS-398 (18), and tested the effects of 10 M C 2 ceramide on the activity of CT in the presence and absence of three concentrations of this compound, 0.1, 1, and 10 M. Neither 0.1 nor 1 M NS-398 had an effect on either basal CT activity or the ability of 10 M C 2 ceramide to inhibit the activity of CT. At a concentration of 10 M, NS-398 had no effect on the response to C 2 ceramide, but it did reduce basal activity (data not shown).
LysoPC inhibits CT activity just as effectively as C 2 ceramide. One explanation for the data presented is that cPLA 2 is activated by TNF-␣ or ceramide and that a metabolite of the reaction catalyzed by cPLA 2 is responsible for the effects on CT activity. We tested this hypothesis by treating cells with either 10 M C 2 ceramide or 2 M 1-palmitoyl-2-lysoPC and measuring the effects on CT activity after 1 h. The effects of both compounds were identical as shown in Fig. 9 . The results indicate that the lysoPC generated through a ceramide-stimulated signaling pathway could be the compound actually responsible for the ceramide-induced inhibition of CT.
CT is not phosphorylated in response to TNF-␣. Changes in the phosphorylation of CT have been observed in connection with certain physiological events such as mitosis (42a), but their significance is not clear. There is no proven cause and effect relationship between CT phosphorylation and its activity (42a). Consistent with that conclusion, we did not observe a strong correlation between the phosphorylation of CT and the changes in its activity induced by TNF-␣. The data are presented in Fig. 10 . CT phosphorylation was reduced to ϳ80% of control value 1-5 h after the cells were presented with 10 ng/ml of TNF-␣, but only the effects at 5 h were statistically significant and then only at P Ͻ 0.1. In some experiments, we ran part of the immunoprecipitates in SDS-PAGE and quantified by autoradiography the amount of [ 32 P]orthophosphate incorporated into the CT band. The results confirmed data obtained by direct counting of the immunoprecipitates. In one experiment, we found that 10 M C 2 ceramide had almost identical effects to those of TNF-␣ (data not shown).
To determine whether there might be changes in the phosphorylation of serine that could have been masked by measuring the phosphorylation of the whole protein, we hydrolyzed the immunoprecipitated protein and separated the phosphorylated amino acids by HPLC. There were no differences in [ 32 P]phosphoserine in cells treated with 100 ng/ml of TNF-␣. We conclude that TNF-␣ and/or ceramide does not exert its inhibition on CT through changes in the phosphorylation of CT; if they did, we would expect significant increases in phosphorylation.
Neither PKC-␣ nor p38 MAPK affect the inhibition by ceramide of orthophosphate incorporation into PC despite their effects on CT activity. CT is the rate-limiting enzymatic activity in the Kennedy pathway for PC synthesis, and changes in its activity should be reflected by differences in synthetic rates, which is consistent with the data presented in the companion paper (53) . However, C 2 ceramide may also inhibit other enzymes in the Kennedy pathway that could likewise affect PC synthesis. To investigate this possibility, we measured the rate of incorporation of [ 32 P]phosphate into cellular PC in cells transfected with dominant negative constructs of PKC-␣ or in nontransfected H441 cells that had been pretreated with 1 and 2 M SB-203580. The results are shown in Fig. 11 . [ 32 P]phosphate incorporation was inhibited by 10 M C 2 ceramide just as effectively as in control H441 cells, even when PKC-␣ or p38 MAPK was blocked, despite their apparent importance in the regulation of CT activity. The results suggest that ceramide inhibits multiple enzymes in the Kennedy pathway, only one of which is CT.
DISCUSSION
The activity of CT is controlled by its association with a lipid environment. CT is a lipid-dependent enzyme, the activity of which is regulated by its interaction with cytoplasmic and nuclear membranes (15) . Diacylglycerol (DAG) and certain other lipids are potent activators (5) . CT shuttles between nuclear and cytoplasmic sites during the course of physiological events, and changes in CT enzymatic activity correlate with its intracellular localization (42a). The mechanisms by which CT is translocated between the cytoplasmic membranes (active) and nuclear membranes (inactive) are unknown, but they are likely to involve associated lipids. Jamil et al. (25) have presented intriguing evidence that activity (and translocation) may be related to the ratio of bilayer-forming to non-bilayer-forming associated lipids.
The signaling pathway for ceramide-induced inhibition of CT involves cPLA 2 . cPLA 2 is an 85-kDa protein that is widely distributed, including in lung tissue (19) . cPLA 2 is an attractive candidate as a regulator of the TNF-␣ or ceramide inhibition of CT. An inhibitor of cPLA 2 , but not of iPLA 2 , nullifies the ceramide-induced inhibition of CT activity (this study). TNF-␣ stimulates cPLA 2 activity, even when given in low concentrations (19) . cPLA 2 has a relatively high specificity for arachidonic acid (20:4) at the sn-2 position (32), and arachidonic acid, in turn, may further activate sphingomyelinases (26) . LysoPC given to H441 cells (data reported here) and to BAC 1.2F5 cells, a macrophage-like cell line (11) , inhibits CT activity. LysoPC also promotes bilayer formation, consistent with the hypothesis of Jamil et al. (25) for the regulation of CT activity, but 9 . Activity of CT in cells given either C2 ceramide or lysophosphatidylcholine (lysoPC). The reagents were given in DMSO in serum-free medium. After 1 h, the cells were washed and lysed for determination of CT activity as described in Fig. 4 . Values are means Ϯ SE from 3 independent experiments. *P Ͻ 0.05 compared with time-matched control cells.
this may be coincidental with the observed inhibition of CT rather than causative. LysoPC itself stimulates Ca 2ϩ influx, thereby potentially activating cPLA 2 , reinforcing the elevation in lysoPC content (20) .
The function of PKC and p38 MAPK may be to activate cPLA 2 . cPLA 2 is regulated by phosphorylation (12) . Activity is dependent on two serine phosphorylation sites: Ser 228 in the lipase sequence and Ser 505 in a proline-dependent kinase sequence. Micromolar concentrations of Ca 2ϩ are required, but the Ca 2ϩ is not involved in the catalytic action but rather serves to anchor the enzyme to lipid membranes. Activated cPLA 2 is principally found at the nuclear membrane.
One of the phosphorylation sites, Ser 505 , is a consensus sequence for proline-dependent kinases. PD-98059 and SB-20358, inhibitors of p42 and p38 MAPKs, respectively, inhibit phosphorylation and activity (12) .
PKC is in the signaling sequence (40) . There are now numerous studies that show that the activation of MAPKs frequently proceeds through a PKC intermediary (for example, Ref. 29) . The role of PKC in this activation is known for one of the classes of MAPK, p42/p44 (extracellular signal-regulated kinase). PKC activates Raf-1 by phosphorylation (directly or possibly through an intermediate) (29) , which functions as a MAPK kinase kinase (i.e., two levels upstream) for p42/p44. The mechanisms by which PKC functions in the other MAPK pathways are unknown; presumably, PKC also activates upstream kinases. In addition, PKC may directly phosphorylate cPLA 2 on several serine sites, but the effect of this phosphorylation is not fully known (12) .
PKCs are activated by TNF-␣ (14), and although the mechanisms of activation are uncertain, two are plausible. TNF-␣ activates PC-specific phospholipase C (PC-PLC) (54) ; this results in increased DAG and stimulation of conventional and novel classes of PKC. PKC is also activated by phosphorylation (42) , but pertinent kinases have not been identified. Like many features of cell signaling, the results of differing studies can be confusing. Thus in some cells, PKC is downregulated by phosphorylation of tyrosines (17) . In others, the phosphorylation of tyrosines (49) or threonines (52) results in its activation.
Leukotrienes may be involved in the ceramide inhibition. We have found that inhibiting the initial enzyme 5-lipoxygenase in the principal pathway of leukotriene synthesis abolishes the ability of C 2 ceramide to inhibit CT. A similar observation has been reported by Arias-Diaz and coworkers (4) . The mechanisms by which leukotrienes interact in this system have not been determined, and we can only speculate as to its pathways. Leukotrienes themselves stimulate the transcription of cytokines (48) , which could amplify the overall effect. In addition, certain of the leukotrienes, LTB 4 (46), LTD 4 (23, 51) , and LTE 4 (51), increase concentrations of intracellular Ca 2ϩ . There are two mechanisms: activation of a phosphatidylinositol-specific PLC through pertussis toxin-sensitive G proteins (23, 51) to hydrolyze L-␣-phosphatidylinositol 4,5-diphosphate to inositol 1,4,5-trisphosphate and release intracellular stores of Ca 2ϩ and the opening of receptor-operated Ca 2ϩ channels through pertussis toxininsensitive G proteins (51). Elevated Ca 2ϩ could then activate a variety of calcium-dependent enzymes including cPLA 2 . This would, of course, result in a renewed synthesis of the arachidonic acid substrate, perpetuating the cycle. Although we consider it plausible that leukotrienes could interact in the signaling process through their effects on intracellular pools of calcium, the data in this study do not directly measure these concentrations. Confirmation of this purported effect will require further exploration in separate studies. Ceramide must also inhibit other enzymes in the pathway(s) for PC synthesis. We have shown that when either PKC-␣ or p38 MAPK is inhibited, C 2 ceramide does not inhibit CT activity. Despite this reversal of CT inhibition, however, C 2 ceramide inhibits PC synthesis. We think that this indicates that C 2 ceramide acts simultaneously on several enzymatic activities, only one of which is CT. We have not identified which of these enzymes are also affected by ceramide, although our previous results suggest that the last enzyme in the Kennedy pathway, CDPcholine:1,2-DAG cholinephosphotransferase, is not affected. An interesting candidate is phosphatidic acid phosphohydrolase (phosphatide phosphatase). Bleasdale and Johnston (9) , in work that is nearly 20 years old, proposed that the activity of phosphatidic acid phosphohydrolase is critical in maintaining the balance between PC, phosphatidylglycerol, and phosphatidylinositol. An inhibition of phosphatidic acid phosphohydrolase should result (by their hypothesis) in a drop in PC, a decrease in phosphatidylglycerol, and an increase in phosphatidylinositol. This is exactly what happens in chronic lung injury (for example, see Ref. 27) .
A hypothesis for the effects of ceramide on CT activity. We suggest that ceramide activates PKC and p38 MAPK and that these contribute to the activation of cPLA 2 by phosphorylation. Activated cPLA 2 hydrolyzes sn-2-arachidonoyl PC to lysoPC and arachidonic acid. LysoPC interacts with the cytoplasmic membrane lipids associated with CT and induces the translocation of CT to the nucleus where it is in an inactive state. Arachidonic acid, through 5-lipoxygenase, generates leukotrienes that further activate cPLA 2 through their elevation of intracellular Ca 2ϩ pools. In addition, these leukotrienes stimulate the production of TNF-␣. In this manner, the pathway is self-sustaining and reinforcing, consistent with the persistent effects of ceramide on CT activity. A signaling scheme consistent with our data is shown in Fig. 12 . Although this scheme is plausible, alternative relationships among the intermediaries are also possible. For instance, our data do not distinguish whether the activation of p38 MAPK in response to ceramide is sequential through PKC-␣ or in parallel. Both PKC-␣ and p38 MAPK activate cPLA 2 (12) . TNF-␣ has been shown to activate p38 MAPK in a variety of cell types (31) , and more recently, Mallampalli and coworkers (35) have shown that it activates p42/p44 MAPK in type II cells. However, these studies do not distinguish whether the activation also involves PKC-␣.
Our data support a central role for cPLA 2 in generating lysoPC and arachidonic acid, a substrate for the synthesis of leukotrienes. Other steps in this hypothesis, particularly the identity and functions of leukotrienes, remain speculative until addressed and confirmed by additional studies.
Multiple mechanisms may be involved in the regulation of CT. Mallampalli and coworkers (36) , in a paper that appeared while this work was being completed, convincingly demonstrated that 500 ng/ml of TNF-␣ reduced CT protein after 24 h of exposure and that this phenomenon may involve proteasome-associated processing. However, there were modest or no changes at shorter times (4 and 12 h). This is in seeming contrast to our observations with 10 M C 2 ceramide in which changes in CT activity were evident as early as 2 h. These differences could relate to differences in cell types, to the fact that C 2 ceramide rapidly traverses cell membranes and thereby acts more rapidly, or from some subtle and unrecognized procedural differences inherent in these two studies. We propose an addi- Fig. 12 . A hypothesis for the events that occur when ceramide inhibits CT activity. LT, leukotriene; PPi, pyrophosphate; DAG, diacylglycerol; cPLA2; cytosolic phospholipase A2.
tional possibility, that signaling through cPLA 2 is a relatively rapid mechanism responsible for the earliest changes in CT activity, whereas protein processing and degradation require longer time intervals. This possibility seems to be hinted at in the study by Mallampalli et al. (36) as evident from comments in the discussion. An alternative explanation is that proteasome-associated processing requires cPLA 2 , but a thorough literature search uncovered no evidence for this.
